BRPI0606833A2 - uso de 2, 4-dihidróxi-3-metilbenzoato, medicamento para o tratamento da hiperplasia prostática, carcinoma de próstata ou da atrofia muscular espino-bulbar, 2,4-dihidróxi-3-metilbenzoato, processo para o isolamento do ácido atrárico a partir de um material biológico e processo para a sìntese de derivados do ácido atrárico - Google Patents

uso de 2, 4-dihidróxi-3-metilbenzoato, medicamento para o tratamento da hiperplasia prostática, carcinoma de próstata ou da atrofia muscular espino-bulbar, 2,4-dihidróxi-3-metilbenzoato, processo para o isolamento do ácido atrárico a partir de um material biológico e processo para a sìntese de derivados do ácido atrárico

Info

Publication number
BRPI0606833A2
BRPI0606833A2 BRPI0606833-2A BRPI0606833A BRPI0606833A2 BR PI0606833 A2 BRPI0606833 A2 BR PI0606833A2 BR PI0606833 A BRPI0606833 A BR PI0606833A BR PI0606833 A2 BRPI0606833 A2 BR PI0606833A2
Authority
BR
Brazil
Prior art keywords
dihydroxy
methylbenzoate
spino
treatment
prostate carcinoma
Prior art date
Application number
BRPI0606833-2A
Other languages
English (en)
Inventor
Hans-Rainer Hoffmann
Rudolf Matusch
Aria Banianhmad
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of BRPI0606833A2 publication Critical patent/BRPI0606833A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/56—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/88—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

USO DE 2,4-DIHIDRóXI-3-METILBENZOATO, MEDICAMENTO PARA O TRATAMENTO DA HIPERPLASIA PROSTáTICA, CARCINOMA DE PRóSTATA OU DA ATROFIA MUSCULAR ESPINO-BULBAR, 2, 4-DIHIDRóXI-3-METILBENZOATO, PROCESSO PARA O ISOLAMENTO DO áCIDO ATRáRICO A PARTIR DE UM MATERIAL BIOLóGICO E PROCESSO PARA A SìNTESE DE DERIVADOS DO áCIDO ATRáRICO. A presente invenção se refere a um método de isolamento do ácido atrárico a partir de um material biológico, derivados de ácido atrárico, a síntese química do mesmo, e o uso do ácido atráríco e dos derivados dos mesmos para o tratamento ou a produção de um medicamento para o tratamento da hiperpíasia prostática benigna, carcinoma de próstata ou atrofia muscular espíno-bulbar e como uma substância básica para o desenvolvimento de outros agentes usados para o tratamento da hiperpiasia prostática benigna, carcinoma de próstata ou atrofia muscular espino-bulbar.
BRPI0606833-2A 2005-02-05 2006-01-28 uso de 2, 4-dihidróxi-3-metilbenzoato, medicamento para o tratamento da hiperplasia prostática, carcinoma de próstata ou da atrofia muscular espino-bulbar, 2,4-dihidróxi-3-metilbenzoato, processo para o isolamento do ácido atrárico a partir de um material biológico e processo para a sìntese de derivados do ácido atrárico BRPI0606833A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005005399A DE102005005399A1 (de) 2005-02-05 2005-02-05 Isolierung von Atrarsäure, Synthese von Atrarsäure-Derivaten sowie deren Verwendung der Atrarsäure und ihrer Derivate zur Behandlung der benignen Prostatahyperplasie und des Prostatakarzinoms
PCT/EP2006/000749 WO2006081997A2 (de) 2005-02-05 2006-01-28 Isolierung von atrarsäure, synthese von atrarsäure-derivaten sowie verwendung der atrarsäure und ihrer derivate zur behandlung der benignen prostatahyperplasie, des prostatakarzinoms und der spinobulbären muskelatrophie

Publications (1)

Publication Number Publication Date
BRPI0606833A2 true BRPI0606833A2 (pt) 2009-07-21

Family

ID=36709710

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606833-2A BRPI0606833A2 (pt) 2005-02-05 2006-01-28 uso de 2, 4-dihidróxi-3-metilbenzoato, medicamento para o tratamento da hiperplasia prostática, carcinoma de próstata ou da atrofia muscular espino-bulbar, 2,4-dihidróxi-3-metilbenzoato, processo para o isolamento do ácido atrárico a partir de um material biológico e processo para a sìntese de derivados do ácido atrárico

Country Status (12)

Country Link
US (1) US8481519B2 (pt)
EP (1) EP1850857B1 (pt)
JP (2) JP2008528648A (pt)
KR (1) KR101223359B1 (pt)
CN (1) CN101115488B (pt)
AU (1) AU2006210043B2 (pt)
BR (1) BRPI0606833A2 (pt)
CA (1) CA2596634C (pt)
DE (1) DE102005005399A1 (pt)
MX (1) MX2007009223A (pt)
WO (1) WO2006081997A2 (pt)
ZA (1) ZA200706107B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012428B2 (en) 2010-11-10 2015-04-21 Janssen Products, Lp Uracyl spirooxetane nucleoside phosphoramidates
KR101811097B1 (ko) * 2011-07-22 2018-01-25 괼, 파완 쿠마르 피지움 추출의 개선된 방법
PL404138A1 (pl) * 2013-05-31 2014-12-08 Warszawski Uniwersytet Medyczny Pochodne kwasu benzoesowego jako inhibitory receptora IL-15Rα
CA2958879A1 (en) * 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
US10993993B2 (en) 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
KR101661332B1 (ko) 2015-05-28 2016-09-29 (의료)길의료재단 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
EP3607949B1 (en) 2018-04-25 2025-02-26 Oncocross Co., Ltd. Dimenhydrinate and calcium pantothenate for preventing and treating muscular disease
KR102600558B1 (ko) * 2021-01-19 2023-11-09 순천대학교 산학협력단 아트라릭산을 포함하는 발모 촉진 및 탈모 방지용 조성물
KR102272616B1 (ko) 2021-03-25 2021-07-05 주식회사 엔테로바이옴 피컬리박테리움 프로스니치 균주를 포함하는 근위축증 예방 또는 치료용 약학적 조성물
KR102329853B1 (ko) 2021-03-25 2021-11-23 주식회사 엔테로바이옴 아커만시아 뮤시니필라 균주를 포함하는 근위축증 예방 또는 치료용 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1177645A (en) 1966-06-10 1970-01-14 Lab Du Dr Debat Plant Extracts and Compositions Containing Same.
US3856946A (en) 1966-06-10 1974-12-24 Debat Lab Prunus africana extract
US3944596A (en) * 1972-11-29 1976-03-16 P.F.W. Beheer B.V. Process for the preparation of 3-mono-alkyl and 3,6-dialkyl-resorcylic esters
US3884843A (en) * 1974-01-31 1975-05-20 Fritzsche Dodge & Olcott Inc Alkyl monomethyl-ringsubstituted-diacetoxy-benzoate perfume compositions
DE3136720C2 (de) * 1981-09-16 1986-05-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur Herstellung von 3-Alkyl-6-methyl-ß-resorcylsäureestern
US5153342A (en) 1989-09-05 1992-10-06 Huls America Inc. Stain-resistant plasticizer compositions and method of making same
US5006585A (en) * 1989-09-05 1991-04-09 Huls America Inc. Stain-resistant plasticizer compositions and method of making same
US6482447B2 (en) * 1999-09-10 2002-11-19 Glenn Braswell Method and composition for the treatment of benign prostate hypertrophy (BPH) and prevention of prostate cancer
US20040198815A1 (en) * 2003-03-31 2004-10-07 Council Of Scientific And Industrial Research Antimicrobial and anticancer properties of methyl-beta-orcinolcarboxylate from lichen (Everniastrum cirrhatum)

Also Published As

Publication number Publication date
ZA200706107B (en) 2008-06-25
CA2596634C (en) 2013-07-23
KR101223359B1 (ko) 2013-01-16
WO2006081997A2 (de) 2006-08-10
KR20070108890A (ko) 2007-11-13
US8481519B2 (en) 2013-07-09
CN101115488A (zh) 2008-01-30
EP1850857B1 (de) 2013-05-22
DE102005005399A1 (de) 2006-08-10
WO2006081997A3 (de) 2006-11-16
JP2008528648A (ja) 2008-07-31
MX2007009223A (es) 2007-09-14
CA2596634A1 (en) 2006-08-10
US20090143466A1 (en) 2009-06-04
CN101115488B (zh) 2011-03-30
JP2013063986A (ja) 2013-04-11
AU2006210043B2 (en) 2011-09-01
EP1850857A2 (de) 2007-11-07
AU2006210043A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
BRPI0515483A (pt) derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
BR0309167A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação
ATE395905T1 (de) Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs
EA200700501A1 (ru) Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
IS2114B (is) Kínasólínafleiður til að meðhöndla æxli
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
CL2007001388A1 (es) Co-cristal de maleato de 2{etil[3-({4-[(5-{2-[(3-fluorfenil)amino]-2-oxoetil}-1h-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}fosfato dihidrogeno de etilo (azd1152), inhibidor de aurora quinasa; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades hiperproliferativas como el cancer.
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
DE502005008058D1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
EA201001241A1 (ru) Спирогетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
BRPI0606833A2 (pt) uso de 2, 4-dihidróxi-3-metilbenzoato, medicamento para o tratamento da hiperplasia prostática, carcinoma de próstata ou da atrofia muscular espino-bulbar, 2,4-dihidróxi-3-metilbenzoato, processo para o isolamento do ácido atrárico a partir de um material biológico e processo para a sìntese de derivados do ácido atrárico
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
BRPI0406596A (pt) Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio
ATE457027T1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase
BRPI0508177A (pt) composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação
EP1817312A4 (en) MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2291 DE 02/12/2014.